Synonym
Oxyprothepine decanoate; Oxyprothepin-decanoate; Oxyprothepin decanoate; Oxyprothepine-decanoate.
IUPAC/Chemical Name
3-(4-(10,11-Dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)piperazinyl)propyl decanoate
InChi Key
SUVSVBSQNAUQJU-UHFFFAOYSA-N
InChi Code
InChI=1S/C32H46N2O2S2/c1-3-4-5-6-7-8-9-15-32(35)36-23-12-18-33-19-21-34(22-20-33)29-24-26-13-10-11-14-30(26)38-31-17-16-27(37-2)25-28(29)31/h10-11,13-14,16-17,25,29H,3-9,12,15,18-24H2,1-2H3
SMILES Code
CCCCCCCCCC(OCCCN1CCN(C2CC3=CC=CC=C3SC4=CC=C(SC)C=C24)CC1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
554.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cesková E, Svestka J, Rysánek R. [Intraindividual comparison of haloperidol decanoate and oxyprothepine in maintenance therapy in schizophrenic psychoses]. Cesk Psychiatr. 1993 Jan;89(1):11-4. Czech. PubMed PMID: 8099534.
2: Buresová A, Bártová D, Svestka J. Comparison of pharmacotherapeutic procedures in the treatment of sexual deviant behaviour. Act Nerv Super (Praha). 1990 Dec;32(4):299-301. PubMed PMID: 1982035.
3: Bártová D, Buresová A, Hajnová R, Svestka J, Tichý P. [The effect of oxyprothepine decanoate, lithium and cyproterone acetate on deviant sexual behavior]. Cesk Psychiatr. 1986 Dec;82(6):355-60. Czech. PubMed PMID: 2879643.
4: David I, Filip V, Hellerová P. [Substitution of fluphenazine decanoate with oxyprothepine decanoate in long-term maintenance therapy in schizophrenia]. Cesk Psychiatr. 1986 Oct;82(5):313-7. Czech. PubMed PMID: 2878734.
5: Filip V, Faltus F, Hanáková S, Janecková E, Raboch J, Dobiásová A, Karen P, Posmurová M. [Oxyprothepin decanoate in maintenance therapy of schizophrenia--a double-blind, standardized controlled study]. Cesk Psychiatr. 1985 Feb;81(1):6-14. Czech. PubMed PMID: 2858269.
6: Balon R, Kabesh Ia, Papezhova G. [Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1982;82(1):116-8. Russian. PubMed PMID: 6121437.
7: Kalvach Z, Hálková E, Bastecký J. Further clinical experience with oxyprothepin-decanoate. Act Nerv Super (Praha). 1981 Dec;23(4):271-2. PubMed PMID: 6121440.
8: Kabes J, Balon R, Hanzlícek L, Skovajsová M, Kozáková H. [Clinical trial of oxyprothepin decanoate (author's transl)]. Cesk Psychiatr. 1980 Feb;76(1):16-25. Czech. PubMed PMID: 6103755.
